Escitalopram — SOLCO HEALTHCARE US, LLC drug label update
Solco Healthcare US, LLC updated the drug label for Escitalopram, clarifying indications for the treatment of Major Depressive Disorder in adults and pediatrics 12 and older, and Generalized Anxiety Disorder in adults and pediatrics 7 and older.
The update affects Solco Healthcare US, LLC, as well as regulatory and medical affairs departments responsible for SSRI labeling and pediatric indication compliance.
This update establishes specific pediatric age thresholds for Escitalopram indications, which may necessitate revisions to marketing materials and clinical protocols. It confirms the regulatory shift toward formally recognized pediatric use for this SSRI in younger populations, specifically as young as age seven for GAD.
Regulatory and labeling teams should ensure that all product literature, including patient medication guides and digital assets, align with these age-specific indications. Compliance departments should verify that internal promotional review processes reflect the age-delimited pediatric approvals for MDD and GAD.
Escitalopram (SOLCO HEALTHCARE US, LLC). 1 INDICATIONS AND USAGE Escitalopram is indicated for the treatment of: • major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. • generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for the: • treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older ( 1 ) • treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years and older ( 1 )
Open in openFDA / FDA.gov